Eli Lilly: positive data with GSK in Covid-19
(CercleFinance.com) - Eli Lilly and GlaxoSmithKline (GSK) announce positive first-line data from the expanded phase II BLAZE-4 trial in low-risk adult patients with mild-to-moderate Covid-19.
Results showed that bamlanivimab 700 maintaining, jointly administered with VIR-7831 500 mg, demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo, thereby meeting the primary endpoint.
"In addition, bamlanivimab administered with VIR-7831 demonstrated a statistically significant reduction compared to placebo in the key virologic secondary endpoints," both pharmaceutical companies added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Results showed that bamlanivimab 700 maintaining, jointly administered with VIR-7831 500 mg, demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo, thereby meeting the primary endpoint.
"In addition, bamlanivimab administered with VIR-7831 demonstrated a statistically significant reduction compared to placebo in the key virologic secondary endpoints," both pharmaceutical companies added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.